SAN DIEGO and KOBE, Japan, March 30 /PRNewswire/ -- ChemDiv, Inc. and Carna Biosciences, Inc. have announced the signing of a collaboration agreement to form a partnership to develop and market annotated kinase focused libraries targeting kinases for various pathways and disease, areas of which have been difficult for industry to produce drug candidates to date. ChemDiv's proprietary chemistry permits small molecule drug development for such kinases while Carna's expertise in kinase assay development and profiling provides rapid screening results for an added annotated component to ChemDiv's kinase libraries
"We are very excited about the possibility of rapidly targeting kinase proteins, that have been known to be involved in cancer and other serious diseases, as the focus of our collaboration," said Nikolay Savchuk, President & CEO of ChemDiv, Inc.
"Carna is able to expand our kinase focused products and services by forming the strategic alliance with ChemDiv," said Kohichiro Yoshino, President of Carna. "Our proprietary technologies and know-how on assay development and screening and ChemDiv's proprietary technologies on kinase focused library development are so complementary that I am confident in the outcome of this collaboration."
About ChemDiv, Inc.
ChemDiv, Inc. (ChemDiv) is a global chemistry-driven contract research organization focused on the delivery of new scientific innovation, products and services that meet the drug discovery needs of its partners. ChemDiv provides partners with access to Discovery outSource(TM), a full service drug discovery capabilities encompassing: medicinal chemistry; pre-clinical development; synthetic chemistry; diverse and focused screening libraries, as well as global logistics. For additional information, please visit http://www.chemdiv.com.
Carna Biosciences, Inc. (www.carnabio.com), founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, as well as providing drug discovery services to pharmaceutical companies, with proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development. The company provides products and services including protein kinases of more than 200, profiling and screening services, assay development services and crystallography products and services.
ChemDiv, Inc.; Carna Biosciences, Inc.
CONTACT: Henrik Konarkowski, Sr. Director, Business Development,+1-858-794-4860, email@example.com; or Kyoto Omoda, Manager, CorporatePlanning of Carna Biosciences, Inc., +81-78-302-7039, firstname.lastname@example.org